Aurinia Pharmaceuticals/$AUPH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Ticker
- $AUPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 128
- Headquarters
- Edmonton, Canada
- Website
- www.auriniapharma.com
AUPH Metrics
BasicAdvanced
$2.2B
7.22
$2.31
-
-
Price and volume
Market cap
$2.2B
52-week high
$19.25
52-week low
$12.07
Average daily volume
784K
Financial strength
Current ratio
6.123
Quick ratio
5.565
Long term debt to equity
0.062
Total debt to equity
0.089
Interest coverage (TTM)
42.87%
Profitability
EBITDA (TTM)
185.42
Gross margin (TTM)
84.58%
Net profit margin (TTM)
97.68%
Operating margin (TTM)
51.61%
Effective tax rate (TTM)
-88.05%
Revenue per employee (TTM)
$2,510,000
Management effectiveness
Return on assets (TTM)
15.34%
Return on equity (TTM)
61.42%
Valuation
Price to earnings (TTM)
7.221
Price to revenue (TTM)
6.829
Price to book
3.39
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
12.411
Free cash flow yield (TTM)
8.06%
Free cash flow per share (TTM)
1.342
Growth
Revenue change (TTM)
21.04%
Earnings per share change (TTM)
320.31%
3-year revenue growth (CAGR)
26.52%
10-year revenue growth (CAGR)
109.24%
3-year earnings per share growth (CAGR)
62.03%
10-year earnings per share growth (CAGR)
15.01%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Analyst projections of the future price of Aurinia Pharmaceuticals stock.
Bulls say / Bears say
LUPKYNIS sales rose 19% in the second quarter to $79.4 million, with the company attributing the increase to further market penetration. Aurinia reiterated 2026 product-sales guidance of $305 million to $315 million. (SEC)
Aurinia generated $85.1 million in operating cash flow in the first half and held $443.1 million in cash, restricted cash and investments at June 30. That provides funding for development and a buffer against setbacks without an immediate need to raise capital. (SEC)
Teva agreed not to launch generic voclosporin in the US before 7 December 2036, subject to certain contingencies and FDA approval. The settlement strengthens the near-term outlook for LUPKYNIS’s market protection. (Aurinia Pharmaceuticals)
The business remains heavily reliant on LUPKYNIS: it generated $153.0 million of Aurinia’s $160.9 million in first-half revenue. A setback to this product would therefore have a large effect on the company’s results. (SEC)
Aritinercept has only recently entered clinical development across four potential indications. Its clinical benefit and commercial value are still unproven, so it cannot yet offset reliance on LUPKYNIS. (SEC)
Aurinia’s 2026 revenue guidance still implies 11%–15% growth, below the 21% increase reported for first-half revenue. That points to slower growth in the second half if the company meets its forecast. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
AUPH News
AllArticlesVideos
Funds containing AUPH
Fund name | Fund size | $AUPH weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.20% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.20% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.20% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.